Aker BP ASA (AKRBP)

The panel's take

Verdict: BALANCED · Conviction: LOW · Last price: NOK 322.30 (as of 2026-07-15)

Aker BP just posted a record quarter for operating cash flow, driven partly by an elevated Brent price tied to renewed Strait of Hormuz tensions, and also raised its capex guidance for two flagship developments. That combination sits at the center of a genuine, not manufactured, disagreement across the panel. Unlike a straightforward "great business, wrong price" setup, this one splits on two separate questions at once: whether the balance sheet is conservatively levered or already stretched — sources disagree meaningfully on the debt figures themselves — and whether the current price is riding a fading geopolitical premium or a durable production-growth story. Because the panel disagrees on the inputs, not just the conclusion, and because multiple lenses flagged real data conflicts across sources on this name, the synthesis here is a lower-conviction BALANCED rather than a clean WAIT-for-a-better-price call.

Key levels

Key resistance sits at NOK 331 — a former support level that now caps the stock after the recent pullback — then the 2026 rally high near NOK 360, with the decade-long range high near NOK 400 as the outer boundary. Key support sits at NOK 307, a historical accumulation zone near NOK 286.50, and a deeper structural level near NOK 270 if the broader pullback extends. The analyst consensus target of roughly NOK 145-330 (average near NOK 253) is unusually wide and sits below the current price at the average, reflecting a genuinely split rating base rather than a clear consensus view.

What legendary investors think

We ran Aker BP past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: This name currently carries a geopolitical oil-price premium and a set of reported balance-sheet figures that don't fully agree across sources — a buyer needs a view on both the Strait of Hormuz situation resolving in a way that sustains elevated oil prices, and on which set of leverage figures is closer to the truth, before this becomes a higher-conviction call in either direction.

The numbers

Metric	Value
Price / Market cap	NOK 322.30 / n/a
P/E (TTM / fwd)	n/a — source conflict (trailing figures range 34x-42x; forward closer to 10x on a post-impairment earnings recovery)
ROE	~14% (FY2025, recovering from a cyclical trough)
Cash margin (implied)	~75%+ at recent realized prices
Dividend yield	~7.7%-8.4%
Debt / equity	~0.87 reported by some sources; others estimate close to net-cash — see debate above
Free cash flow	n/a — not independently confirmed this quarter

Figures as of 2026-07-15; sourced from Aker BP Q1/Q2 2026 results and investor materials, Simply Wall St, GuruFocus, and stockanalysis.com. Multiple sources disagreed materially on leverage and trailing P/E for this name; figures above are presented as reported, with the conflict flagged rather than resolved.

The bottom line

Aker BP is a genuinely low-cost North Sea operator posting record cash flow into an oil-price environment inflated by renewed Middle East conflict — the operational story is sound and not in serious dispute. What keeps this at a BALANCED rather than a cleaner call is that the panel's disagreement runs deeper than price: reported balance-sheet figures for this name conflict meaningfully across sources, and the macro debate over whether current oil prices reflect a durable trend or a fading war premium remains genuinely unresolved among the lenses. The dividend yield and low-cost asset base offer real downside cushion, and two major developments due online in 2027 are a credible medium-term catalyst — but with the inputs themselves in dispute, a lower-conviction BALANCED is a more honest synthesis than forcing a directional call. The clearest next test is whether the Strait of Hormuz situation and Brent prices stabilize or reverse over the coming months, alongside confirmation of on-budget execution on the pending developments.

The panel's take

Verdict: WAIT · Conviction: LOW · Last price: NOK 327.80 (as of 2026-07-18) · Changed from BALANCED

What changed since 2026-07-15:

• Price: NOK 322.30 → 327.80 (+1.7%) — a modest continued drift higher within the same Strait of Hormuz-driven Brent premium noted last week.
• Panel: 1 of 6 → 0 of 6 now Bullish (the Asymmetric Bargainer flipped Bullish→Neutral; the Macro Opportunist flipped Bearish→Neutral) — the panel has converged from a business-level split onto one shared blocker, the unresolved debt-to-equity dispute, rather than genuine disagreement on the business itself.
• Trigger: the Q2 report resolving the leverage dispute, or a confirmed close through NOK 331 versus a break back toward NOK 307.
• Verdict: BALANCED → WAIT

This is a genuine shift in the shape of the panel's disagreement, not just a price update. The remaining split used to run along business lines — cost-structure downside protection versus a fading war premium — and now runs along a single unresolved data question: which of the two conflicting debt-to-equity figures is closer to true. Until that clears, or the chart confirms a direction, several lenses would rather wait than force a call — a price/timing-and-data-resolution problem sitting on top of a business nobody on the panel is actually attacking.

Key levels

Key resistance sits at NOK 331 — the Supertrend line and a former-support-turned-resistance level the stock is currently pressed just underneath — then the 2026 rally high near NOK 360, with the decade-long range high near NOK 400 as the outer boundary. Key support sits at NOK 307, a historical accumulation zone near NOK 286.50, and a deeper structural level near NOK 270 if the pullback extends. The analyst consensus target of roughly NOK 145-330 (average near NOK 253) still sits below today's price at the average, reflecting the same split rating base as last week rather than a resolved consensus view.

What legendary investors think

We ran Aker BP past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: With the business itself unchallenged but the leverage figures still in dispute and price stuck directly under its own Supertrend line, does the Q2 print or a confirmed technical break resolve first — and which direction does it point?

The numbers

Metric	Value
Price / Market cap	NOK 327.80 / n/a
P/E (TTM / fwd)	n/a — source conflict (trailing figures range 35x-43x; forward closer to 10x on a post-impairment earnings recovery)
ROE	~14% (FY2025, recovering from a cyclical trough)
Cash margin (implied)	~75%+ at recent realized prices
Dividend yield	~7.6%-8.3%
Debt / equity	~0.87 reported by some sources; others estimate close to net-cash — see debate above
Free cash flow	n/a — record operating cash flow referenced but not independently confirmed this quarter

Figures as of 2026-07-18; sourced from Aker BP Q1/Q2 2026 results and investor materials, Simply Wall St, GuruFocus, and stockanalysis.com. Multiple sources continue to disagree materially on leverage and trailing P/E for this name; figures above are presented as reported, with the conflict flagged rather than resolved.

The bottom line

A Q2 print that resolves the leverage figure toward the lower, near-net-cash estimate would likely pull the lone bearish voice toward neutral and open the door to a BALANCED or better; a print that confirms the higher ~0.87x reading, or one that pairs with a break below NOK 307, would instead harden the case for an outright Bearish read. A confirmed close above NOK 331 without a leverage resolution would leave the panel split on interpretation rather than data — price momentum running ahead of an unresolved balance sheet, not a green light. Of the two named triggers, the Q2 print is the more decisive: it resolves the specific data conflict driving five of six lenses to Neutral, not just the chart.

The panel's take

Verdict: BALANCED · Conviction: LOW · Last price: NOK 340.50 (as of 2026-07-25) · Changed from WAIT

What changed since 2026-07-18:

• Price: NOK 327.80 → NOK 340.50 (+3.9%) — a decisive close through the panel's own named NOK 331 trigger, briefly topping NOK 347 intraweek before settling back to the same close two weeks running.
• Panel: 0 of 6 → 1 of 6 now Bullish (the Macro Opportunist flipped Neutral→Bullish on the confirmed technical break plus an escalating Iran/Hormuz oil premium); 1 of 6 stays Bearish (the Margin-of-Safety Hunter, unchanged, on valuation); the Intrinsic-Value Modeler's conviction moved Low→Medium as the leverage fog cleared. Net: a modestly more constructive panel, not a converged one.
• Catalyst: Q2 2026 results (published 2026-07-15) delivered record $3.1B operating cash flow, confirmed $1.3B positive free cash flow, and an EPS beat ($1.15 vs. ~$0.96 consensus) — turning last week's "FCF: n/a" and disputed leverage figure into hard data. The catch: sources still disagree on the resolved number itself, with readings ranging from a healthy 0.55x to a less comfortable 0.77x-0.85x.
• New risk/offset: CapEx guidance was raised to $6.8-7.2B for the Yggdrasil/Valhall build-out, and the analyst consensus average (NOK 329.56 across 16 analysts) has now caught up to the current quote — the discount-to-consensus argument that supported patience last week no longer holds.
• Verdict: WAIT → BALANCED.

Last week's call was explicitly a timing problem — wait for the Q2 print or a confirmed technical break to clear the fog. Both have now happened, and both point the same direction on the surface: leverage improved, cash flow is real, and the chart confirmed the breakout level. But resolving the data didn't resolve the debate — it just moved it. The panel no longer agrees on whether the improved leverage figure is genuinely healthy or merely less bad, and more importantly, the price move that accompanied the good news erased the valuation gap that made waiting attractive. A stock trading essentially at its own analyst consensus, on a still-disputed balance-sheet number, with one lens actively bearish on multiple grounds and another leaning on a geopolitical premium it admits could reverse, reads as a business worth holding through the noise rather than one worth chasing or abandoning.

Key levels

The ladder has shifted up one full notch from last week. The old resistance at NOK 331 (the Supertrend line) has flipped to first support — only two weeks old and not yet proven as a genuine floor — with the prior support at NOK 307-308 now sitting one tier deeper, and the NOK 286.50 Stage-1 base top still the key structural/accumulation floor if the pullback extends further than that. Overhead, a cluster of prior swing-high closes forms resistance at NOK 351-355, then a double-top zone near NOK 360-368, with the dataset all-time high near NOK 374 and the psychological NOK 400 round number as the outer boundary. The analyst consensus average of NOK 329.56 now sits just below the current quote rather than well below it, meaning the market has largely closed the gap the consensus figure used to flag.

What legendary investors think

We ran Aker BP past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: With both named triggers fired but landing on a fairly-valued stock rather than a discounted one, does the market hold NOK 331 on a retest and clear the NOK 351-355 shelf next — confirming the Macro Opportunist's read — or does a Brent pullback reopen the NOK 307/286.50 support test the rest of the panel is still implicitly bracing for?

The numbers

Metric	Value
Price / Market cap	NOK 340.50 / n/a
P/E (TTM / fwd)	n/a — source conflict persists (trailing figures cited 27.9x-39.94x; forward closer to 7x-10x on this quarter's Brent-premium earnings)
ROE	~14% (unchanged from prior quarter; no new figure surfaced this week)
Cash margin (implied)	~75%+ at recent realized prices
Dividend yield	~7.5% (Q2 dividend $0.6615/share, annualized $2.646, at NOK 340.50; ex-div 2026-07-20, paid ~2026-07-28)
Debt / equity	Disputed even post-Q2: ~0.55x per several sources vs. ~0.77x-0.85x per others — see debate above
Free cash flow	$1.3B for the quarter, confirmed (resolves last week's "n/a" gap)
Analyst consensus target	NOK 329.56 average (range NOK 200-390, 16 analysts: 5 buy / 9 hold / 2 sell)

Figures as of 2026-07-25; sourced from Aker BP Q2 2026 results and earnings-call materials (Investing.com, GuruFocus, StockTitan, 2026-07-15), Investing.com consensus estimates (retrieved 2026-07-25), and TradingView (retrieved 2026-07-25). Leverage and trailing P/E continue to disagree materially across sources even after the Q2 print; figures above are presented as reported, with the conflict flagged rather than resolved.

The bottom line

A confirmed close above the NOK 351-355 shelf with expanding volume, alongside a subsequent quarter confirming the more favorable ~0.55x leverage reading, would tip this toward an outright Bullish read across more of the panel. A slide back below NOK 331 — whether from a Brent pullback, a de-escalation headline, or the disputed leverage figure resolving toward the Moat Compounder's less comfortable ~0.85x — would reopen the NOK 307/286.50 support test and revive the case for stepping back to Bearish. For now, the business quality is unchallenged, the price is no longer a bargain, and the panel is genuinely split rather than converged — the textbook shape of a BALANCED verdict, not a WAIT: there's now enough information to underwrite the position, just not enough conviction on either side to move it.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 334.5 · Changed from BALANCED

What changed since 2026-07-25:

• Price: 340.5 → 334.5 (-1.76%)
• Panel: 1 of 6 → 1 of 6 now Bullish — composition also changed: added The Forensic Skeptic, The GARP Operator; removed The Margin-of-Safety Hunter, The Quality Rationalist
• Trigger: BUY trigger: A weekly close above 342.4 (confirms pullback resolved) OR a retest of 307–324 support zone with a bullish MACD turn and confirming fundamental catalyst (e.g., debt reduction announcement, Q3 beat). SELL trigger: A weekly close below 322.9 (breach of EMA20/Fib 38.2% cluster), confirming the correction is deepening, especially if accompanied by oil below $55 or a dividend cut.
• Verdict: BALANCED → WAIT

Three weeks ago the panel leaned BALANCED at LOW conviction: the capex-crossover thesis was visible but unproven, and the price at 340.5 sat even closer to resistance. Today the verdict shifts to WAIT at MEDIUM conviction — the price has eased toward the support zone (down 1.8%), but the real driver is that the Q1 beat and estimate revision momentum have hardened the bullish conviction on the business side while the price/timing bottleneck remains the same. The debate has sharpened, not resolved: the bulls are more confident in the thesis, the bears are more vocal about the debt, and everyone agrees 334.5 still isn't the right place to act.

The split is BUY vs WAIT, not BUY vs SELL — the fundamental bears (The Moat Compounder, The Asymmetric Bargainer) object on business quality/debt/moat rather than price alone, but the structural bulls (The Macro Opportunist, The Intrinsic-Value Modeler) see a real post-capex inflection worth buying on a pullback. No voice advocates selling the uptrend outright (the fundamental-scout's SELL is low-conviction and contradicted by strong TTM recovery data). The decisive factor is the price/timing bottleneck: even the bulls want to buy at 307–324 support, not at 334.5 below resistance. That makes this a clean WAIT — the business debate is noisy but the operational recovery signals (Q1 beat, estimate revisions) tilt the synthesis away from SELL, while the poor entry price tilts it away from BUY.

Key levels

What legendary investors think

We ran Aker BP ASA past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the operational recovery from FY2025's trough — visible in earnings beats and estimate revisions — translate into durable free cash flow that reduces debt before the next commodity downturn tests a balance sheet already flagged as distressed?

The bottom line

Watch the 322.9-324.3 support cluster — a weekly close below that band with volume would signal the correction is deepening, and with the Altman Z-score already at 1.10, a breach could accelerate selling toward the 290-307 zone. On the upside, a weekly close above 342.4 shifts the technical picture from "pullback within uptrend" to "pullback resolved," but without a fundamental catalyst — specifically, a Q3 2026 earnings release showing debt reduction or a dividend-policy reset — the breakout would lack staying power. The next earnings report (expected October 2026) is the event that could answer the core question: is free cash flow being used to deleverage or to keep funding an unsustainable dividend? Until then, oil price trajectory remains the swing factor: above $70/bbl the post-capex story works; below $55 the balance-sheet risk dominates everything.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 330.1

What changed since 2026-08-01:

• Price: 334.5 → 330.1 (-1.32%)
• Panel: 1 of 6 → 1 of 5 now Bullish — composition also changed: added none; removed The Macro Opportunist
• Trigger: BUY on: (1) pullback to NOK 295–310 on no fundamental deterioration, or (2) weekly close above 336.46 with weekly MACD histogram turning positive. SELL if: weekly close below 303.40 (weekly EMA50), which would signal Stage 2 uptrend failure.
• Verdict: WAIT (unchanged)

The prior panel (August 1) also landed at WAIT, but with six voices including The Macro Opportunist. The shift to five voices this round sharpens the picture rather than changing it. The stock has drifted lower from NOK 334.5 to 330.1, edging closer to the consensus accumulation zone (295 to 310) without yet reaching it, and removing the macro overlay places the burden squarely on price and timing: the business case is intact, the valuation has not improved enough to trigger a BUY, and the same specific pullback levels remain the gate.

Four of five cautious voices want to own this business, just at a better price. Their objection is about price and timing, not thesis quality. The lone business-level objector (The Moat Compounder) is outweighed by the structural split: this is a BUY versus WAIT, not a BUY versus SELL. The identifiable trigger is a pullback into the 295 to 310 zone (the monthly EMA cluster) or a weekly MACD re-cross above signal on strength above 336.46. WAIT is the correct call, not BALANCED, because price is the single blocker and a specific zone has been named.

Key levels

What legendary investors think

We ran Aker BP ASA past a panel of 5 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the 2027 FCF inflection, visible and well-telegraphed as it is, justify paying up now at NOK 330, or does a commodity business with no moat, a stretched dividend, and peak-year capex demand a pullback into the 295 to 310 zone before the balance of upside and downside truly tilts toward the buyer?

The bottom line

• Trigger to confirm the breakout: A weekly close above NOK 336.46 with the weekly MACD histogram turning positive would negate the bearish crossover and signal momentum has shifted back in favor of the FCF-inflection thesis.
• The pullback accumulation zone: A move into NOK 295 to 310 with no fundamental deterioration (no capex overrun announcement, Brent holding above $60) would put the stock into the monthly EMA cluster and volume POC, satisfying the margin-of-safety requirement for four of the five panelists.
• Risk to monitor: A weekly close below NOK 303.40 (the weekly EMA50) would signal failure of the Stage 2 uptrend and open a path toward the monthly POC near NOK 265.
• Next catalyst: Q2 2026 earnings will test whether the CEO's stated $127-a-barrel realized price is sustained. If actual realizations come in drastically below that figure, management credibility, and the bull thesis with it, would be materially damaged.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 345.6

What changed since 2026-08-08:

• Price: 330.1 → 345.6 (+4.70%)
• Panel: 1 of 5 → 1 of 6 now Bullish — composition also changed: added The Macro Opportunist, The Quality Rationalist; removed The Moat Compounder
• Trigger: BUY on either (a) a pullback to the NOK 310-323 zone (monthly 50% Fib at 310.50, weekly 38.2% Fib at 322.92) with a bullish reversal candle, or (b) a weekly close above NOK 373.80 with volume confirming the correction is over and the next markup leg has begun. SELL if weekly close below NOK 303.97 (weekly EMA50), breaking the Stage 2 structure.
• Verdict: WAIT (unchanged)

Since the prior WAIT verdict at NOK 330.1, the stock has drifted 4.7% higher to 345.6, compressing the asymmetry further: it sits even closer to the 354-374 resistance band without testing either the support zone (310-323) or the breakout level (373.80) that would resolve the entry-timing question. Two new voices joined the panel this time (The Quality Rationalist and The Macro Opportunist), and neither found the price compelling enough to shift the call: both landed Neutral, reinforcing rather than breaking the existing WAIT consensus.

The split is structurally a BUY vs WAIT — not a business-quality dispute. Every voice, including the bulls (The Forensic Skeptic, Technical Scout), and neutrals (The Intrinsic-Value Modeler, The Asymmetric Bargainer, The GARP Operator, The Quality Rationalist, The Macro Opportunist), acknowledges that Aker BP is a well-run, low-cost operator with a valid 'peak capex → FCF inflection' thesis. The single blocker is price: at NOK 345.60 the stock sits between support (336) and resistance (354-374), compressing asymmetry. The consensus ideal entry is NOK 310-323, where monthly support, weekly Fib levels, and the weekly EMA50 converge to provide a defined risk floor. No voice argues the business is broken or deteriorating — it is purely an entry-timing objection, which maps to WAIT, not BALANCED.

Key levels

What legendary investors think

We ran Aker BP ASA past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the market's current anchoring to the 2026 peak-capex year create a genuine mispricing of the 2027 FCF inflection, or is the stock fairly pricing in the commodity risk and normalized earnings that a 15.5x cyclical multiple already reflects?

The bottom line

• Entry zone to watch: A pullback into NOK 310-323 (monthly 50% Fib at 310.50, weekly 38.2% Fib at 322.92) with a bullish reversal candle would flip the asymmetry decisively in favor of a BUY across the panel.
• Breakout confirmation: A weekly close above NOK 373.80 with above-average volume would confirm the correction is over and the next Stage 2 markup leg has begun, removing the entry-timing objection.
• Structural risk line: A weekly close below NOK 303.97 (the weekly EMA50) would break the Stage 2 uptrend structure that underlies every constructive read on this name, converting the WAIT to a SELL.
• Next catalyst: 2027 capital-allocation guidance, expected alongside Q4 2026 results, should provide the first concrete FCF inflection numbers the market can underwrite rather than merely model.
• Commodity tripwire: Sustained Brent crude below $60/barrel would undercut the CFO's $50 stress-test margin of comfort and trigger earnings revisions that compress the P/E floor below the current valuation support.

The panel's take

Verdict: BALANCED · Conviction: MEDIUM · Last price: 354.8 · Changed from WAIT

Panel: 1 Bullish · 4 Neutral · 1 Bearish → BALANCED

What changed since 2026-08-15:

• Price: 345.6 → 354.8 (+2.66%)
• Panel: 1 of 6 → 1 of 6 now Bullish — composition also changed: added The Activist Catalyst; removed The Macro Opportunist
• Trigger: BUY on a pullback into the 328–336 NOK zone (weekly EMA20 to monthly Fib 38.2%) with a bullish reversal candle confirming support. SELL on a weekly close below 328.70, breaking the Stage 2 uptrend structure.
• Verdict: WAIT → BALANCED

The prior WAIT trigger required either a pullback to 310–323 or a breakout above 373.80. Neither materialized. Price drifted 2.7% higher to 354.8 without touching either level, leaving all six voices stuck between a technical resistance zone that has not broken and a support zone that has not been tested. With the bull case (+17% to 415 on $80 Brent) and bear case (late-cycle reversal risk from a 46% rally) roughly cancelling, the arithmetic lands at BALANCED.

The prior WAIT trigger (pullback to 310–323 or breakout above 373.80) did not fire — price drifted to 354.8 without touching either level. Four of six voices now say BALANCED: the Stage 2 uptrend and record operating cash flow argue against selling, but at 7.8% above the consensus target of 329 and with the weekly MACD rolling over, there is no edge in adding new money. The lone bull (The Intrinsic-Value Modeler) sees ~17% upside to 415 on an $80 Brent base case; the lone bear (The GARP Operator) warns the 46% rally from the 52-week low and management's euphoric tone are classic late-cycle signals. With the bull and bear cases roughly cancelling and the neutrals unwilling to commit either way, BALANCED is the arithmetic reading.

Key levels

Key support at 342–336 (weekly Fib 23.6% and monthly Fib 38.2%) is the first zone where dip-buyers stepped in during the 2026 advance; 328.70 is the weekly EMA20, the trend filter that has contained every pullback in the current Stage 2 markup. Key resistance at 368–374 (monthly Fib 23.6% and the 52-week high at 373.80) is the band that rejected price on the most recent weekly swing. The analyst consensus target of 329.25 sits inside the support zone, marking the level where fundamental and technical buyers converge.

What legendary investors think

We ran Aker BP ASA past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: At 354.8 NOK, does the FCF-inflection narrative after peak capex in 2026 justify paying above consensus, or does the commodity dependency and leveraged balance sheet make waiting for a pullback into the 328–336 zone the only rational move?

The bottom line

• Trigger to confirm the breakout: A weekly close above 373.80 with re-accelerating MACD would signal the Stage 2 uptrend is extending and the bull case to 415 is in play.
• Price zone for accumulation: A pullback into the 328–336 NOK zone (weekly EMA20 to monthly Fib 38.2%) with a bullish reversal candle would offer the margin of safety that four of six voices currently lack.
• Risk to monitor: A weekly close below 328.70 breaks the Stage 2 uptrend structure and would flip the call to SELL, confirming the late-cycle bear case.
• Next catalyst: H2 2026 capex guidance and the first credible post-peak maintenance capex estimate are the single most important numbers to validate or invalidate the FCF-inflection thesis.
• Further out: The Brent forward curve holding above $80 through 2027–28 is required for the Intrinsic-Value Modeler’s base case to hold and for the dividend growth commitment to remain credible.